Recent advances in developing degraders & inhibitors of lysine methyltransferases.
Curr Opin Chem Biol
; 76: 102356, 2023 10.
Article
em En
| MEDLINE
| ID: mdl-37379717
ABSTRACT
Over the last several decades, there has been continued interest in developing novel therapeutic approaches targeting protein lysine methyltransferases (PKMTs). Along with PKMT inhibitors, targeted protein degradation (TPD) has emerged as a promising strategy to attenuate aberrant PKMT activity. Particularly, proteolysis targeting chimeras (PROTACs) effectively eliminate PKMTs of interest, suppressing all enzymatic and non-enzymatic functions. PROTACs and other TPD approaches add new depth to PKMT research and novel therapeutics discovery. This review focuses on recent advances in PKMT degrader and inhibitor development over the last several years.
Palavras-chave
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Histona-Lisina N-Metiltransferase
/
Lisina
Idioma:
En
Ano de publicação:
2023
Tipo de documento:
Article